Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 64
- Registration Number
- NCT00171132
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 317
- Registration Number
- NCT00170924
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00171028
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 109
- Registration Number
- NCT00171353
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT00171119
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 86
- Registration Number
- NCT00171080
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00171106
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Prevention of CHOP-induced Chronic Cardiotoxicity
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Osaka City University
- Target Recruit Count
- 150
- Registration Number
- NCT00162955
- Locations
- 🇯🇵
Graduate School of Medicine, Osaka City University, Osaka, Japan
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 885
- Registration Number
- NCT00153023
- Locations
- 🇨🇿
District Hospital Tabor, Tabor, Czech Republic
🇫🇷Hopital A.Mignot, Le Chesnay, France
🇨🇿University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Target Recruit Count
- 3031
- Registration Number
- NCT00149227
- Locations
- 🇯🇵
Kyoto Prefectural University of Medicine, Kyoto, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.